ABSTRACT
Hypersensitivity Injection-site extravasation (1999): Fleming A+, J Hand Surg [Br] 24, 390 Injection-site inflammation Injection-site necrosis Injection-site reactions (sic) (3-20%) Injection-site ulceration Mucositis (1999): Ormrod D+, Drugs Aging 15, 389 Myalgia (1995): Fountzilas G+, Med Pediatr Oncol 24, 23 (55%) Oral ulceration Phlebitis Stomatitis (1995): Fountzilas G+, Med Pediatr Oncol 24, 23 (1991): Carmo-Pereira J+, Cancer Chemother Pharmacol 27, 394 (35%) (1991): Fountzilas G+, Tumori 77, 232 (24%) (1986): Kimura K+, Gan To Kagaku Ruoho (Japanese) 13, 2440 (12.5%) (1986): Sakata Y+, Gan To Kagaku Ryoho (Japanese) 13, 1887 (1980): Bonfante V+, Recent Results Cancer Res 74, 192
Trade name: Inspra (Pharmacia) Indications: Hypertension Category: Antihypertensive; Selective aldosterone blocker Half-life: 4-6 hours Clinically important, potentially hazardous interactions with: ACE inhibitors,
angiotensin II receptor antagonists, erythromycin, fluconazole, grapefruit juice, itraconazole, ketoconazole, saquinavir, St John’s wort, verapamil
Reactions
Skin Flu-like syndrome (2%)
Other Cough (2%)
Dizziness (3%) Fatigue (2%) Gynecomastia (males <1%) Headache Mastodynia (males <1%)
Synonyms: erythropoietin; EPO Trade names: Epogen (Amgen); Procrit (Ortho) Other common trade names: Epoxitin; Eprex; Erypo Indications: Anemia Category: Colony stimulating factor; Growth factor Half-life: 4-13 hours (in patients with chronic renal failure)
Reactions
Skin Acne
(1989): Faulds D+, Drugs 38, 863 Angioedema (1-5%) Dermatitis (1993): Hardwick N+, Contact Dermatitis 28, 123 Edema (17%) Exanthems (1990): Schröder-Kolb B, Derm Beruf Umwelt (German) 38, 12 (papular) Lichenoid eruption (1997): Puritz E, Smithtown, NY (from Internet) (observation) Photosensitivity (1992): Harvey E+, J Pediatr 121, 749 Pruritus (1990): Schröder-Kolb B, Derm Beruf Umwelt (German) 38, 12 (papular)
(1989): Faulds D+, Drugs 38, 863 Rash (sic) (1-10%) Urticaria
Hair Hair-alopecia
(2001): Reddy V+, Nephrol Dial Transplant 16(7), 1525 Hair-alopecia totalis (2001): Reddy V+, Nephrol Dial Transplant 16(7), 1525 Hair-hypertrichosis (1991): Kleiner MJ+, Am J Kidney Dis 18, 689
Other Anaphylactoid reactions
Headache Hypersensitivity (<1%) Injection-site pain (1998): Veys N+, Clin Nephrol 49, 41 Injection-site reactions (sic) (7%) Injection-site thrombophlebitis Injection-site ulceration (1997): Siegel DM, New York, NY (from Internet) (observation) Myalgia Paresthesias (11%) Porphyria cutanea tarda (1992): Harvey E+, J Pediatr 121, 749
Trade name: Teveten (Biovail) Indications: Hypertension Category: Angiotensin II receptor antagonist; Antihypertensive Half-life: 5-9 hours
Reactions
Skin Angioedema
Diaphoresis (<1%) Eczema (sic) (<1%) Exanthems (<1%)
Facial edema (<1%) Furunculosis (<1%) Herpes simplex (<1%) Hot flashes (<1%) Peripheral edema (<1%) Pruritus (<1%) Purpura (<1%) Rash (sic) (<1%)
Other Burning mouth syndrome
(2002): Castells X+, BMJ 325(7375), 1277 Cough (2001): Rake EC+, J Hum Hypertens 15(12), 863 (5%) Dysgeusia (2002): Castells X+, BMJ 325(7375), 1277 Gingivitis (<1%) Myalgia Paresthesias (<1%) Tendinitis (<1%) Tremor (<1%) Xerostomia (<1%)
Trade name: Integrilin (Millennium) (Schering) Indications: Acute coronary syndrome, unstable angina Category: Antiplatelet; Platelet aggregation inhibitor Half-lifc: 2.5 hours Clinically important, potentially hazardous interactions with: fondaparinux
Reactions
Skin None
Other Anaphylactoid reactions (<1%)
Injection-site reactions (sic)
